Our investment recommendation module complements current
analysts and expert consensus on Cryolife. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time.
The company dividends can provide a clue to the current value of the stock. This firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
How important is CryoLife's Liquidity
CryoLife
financial leverage refers to using borrowed capital as a funding source to finance CryoLife ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. CryoLife financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to CryoLife's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of CryoLife's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between CryoLife's total debt and its cash.
A Deeper Perspective
Institutional investors typically avoid acquiring a high percentage of Cryolife stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Cryolife is distributed among investors.
Ownership Allocation
Cryolife retains a total of 39.12 Million outstanding shares. The majority of Cryolife
outstanding shares are owned by
other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cryolife to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cryolife. Please pay attention to any change in the institutional holdings of Cryolife as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
| Retail Investors11.92% | | Institutions84.35% |
| Retail Investors | 11.92 |
| Insiders | 3.73 |
| Institutions | 84.35 |
| 2018 | 2019 | 2020 | 2021 (projected) |
Operating Income | 9.31 M | 17.04 M | 2.44 M | 2.51 M | Operating Expenses | 163.67 M | 165.97 M | 165.34 M | 148.08 M |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cryolife has an asset utilization ratio of 142.33 percent. This suggests that the company is making $1.42 for each dollar of assets. An increasing asset utilization means that Cryolife is more efficient with each dollar of assets it utilizes for everyday operations.
| Assets Non Current598.6 M | Goodwill525.6 M | |
| Current Assets | 203.08 Million | 15.28 |
| Assets Non Current | 598.62 Million | 45.05 |
| Goodwill | 525.57 Million | 39.55 |
| Tax Assets | 1.48 Million | 0.11 |
Cryolife implied volatility may change after the rise
The semi variance is down to 2.62 as of today. Cryolife has relatively low volatility with skewness of 5.05 and kurtosis of 34.78. However, we advise all investors to independently investigate Cryolife to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cryolife's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cryolife's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Take On Cryolife
While other entities within the medical devices industry are still a little expensive, even after the recent corrections, Cryolife may offer a potential longer-term growth to investors. In closing, as of the 1st of May 2021, our ongoing 30 days Buy-Hold-Sell recommendation on the company is
Hold. We believe Cryolife is
fairly valued with
below average probability of distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of CryoLife. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
